Core Insights - SS Innovations International, Inc. reported record quarterly revenue of $10.0 million, a 121.8% increase from $4.5 million in Q2 2024, driven by higher sales of the SSi Mantra 3 surgical robotic system [5][4] - Gross profit more than tripled to $5.9 million, reflecting a gross margin expansion to 59.1% from 31.9% in the same quarter last year [5][4] - The company narrowed its net loss to $0.3 million, compared to a net loss of $4.1 million in Q2 2024, indicating significant operational improvements [5][4] Second Quarter 2025 Overview - Revenue increased by 121.8% to $10.0 million from $4.5 million in Q2 2024 [5] - Gross margin expanded to 59.1% from 31.9% in Q2 2024 [5] - Gross profit rose 311.4% to $5.9 million from $1.4 million in Q2 2024 [5] - Net loss decreased to $0.3 million, or $(0.00) per diluted share, from a net loss of $4.1 million, or $(0.02) per diluted share, in Q2 2024 [5] First Half 2025 Overview - Revenue for the first half of 2025 increased by 85.6% to $15.1 million from $8.1 million in the first half of 2024 [5] - Gross margin expanded to 46.3% from 26.6% in the first half of 2024 [5] - Gross profit rose 223.3% to $7.0 million from $2.2 million in the first half of 2024 [5] - Net loss for the first half of 2025 was $5.9 million, or $(0.03) per diluted share, compared to a net loss of $14.0 million, or $(0.08) per diluted share, in the first half of 2024 [5] Business Highlights - SSi Mantra surgical robotic system installations totaled 23 in Q2 2025, a 130% increase from 10 installations in Q2 2024 [5] - Cumulative installed base of SSi Mantra systems reached 105 across seven countries, with cumulative surgeries totaling 4,657 [5] - The company plans to submit a 510(k) application for multiple indications for the SSi Mantra 3 to the FDA by the end of September 2025 [4][5] CEO Commentary - The CEO emphasized the company's commitment to expanding access to robotic surgery and highlighted the successful execution of strategic initiatives leading to strong revenue growth [4] - The SSi Mantra 3 system has achieved several "world firsts" in robotic telesurgery and cardiac procedures [4] - The company is on track for European Union CE marking certification by late 2025 [4]

Core Viewpoint - SS Innovations International, Inc. successfully completed the world's first intercontinental robotic cardiac telesurgery, demonstrating the advanced capabilities of its SSi Mantra 3 surgical robotic system and paving the way for improved access to complex cardiac care globally [1][4]. Company Achievements - The cardiac procedure performed was a robotic atrial septal defect closure, conducted remotely from Strasbourg, France, to Indore, India, over a distance of more than 4,000 miles [2]. - A total of 35 telesurgeries, including 10 cardiac procedures, have been successfully completed using the SSi Mantra surgical robotic system, showcasing its effectiveness in complex surgeries [5]. - The SSi Mantra system has been clinically validated in over 100 different types of surgical procedures in India, with more than 5,000 multi-specialty surgeries performed without device-related adverse events [5][9]. Technological Innovation - The SSi Mantra surgical robotic system features a modular design with 3 to 5 robotic arms, a 3D 4K monitor, and advanced imaging capabilities, enhancing the safety and efficiency of surgical procedures [9]. - The system's telesurgery capabilities address traditional barriers related to travel, time, cost, and surgical accessibility, aiming to create a more equitable medical standard [4]. Regulatory Approval - SS Innovations is the only surgical robotic company to receive regulatory approval from India's Central Drugs Standard Control Organization (CDSCO) for both teleproctoring and telesurgery, highlighting its compliance with safety and efficacy standards [6].

Core Insights - SS Innovations International, Inc. has successfully completed the world's first robotic telesurgery for weight loss using the SSi Mantra 3 surgical robotic system, marking a significant milestone in the field of robotic surgery [2][3][5] Company Overview - SS Innovations is dedicated to making robotic surgery affordable and accessible globally, with a focus on innovative surgical robotic technologies [2][7] - The company is headquartered in India and aims to expand its global presence with user-friendly and cost-effective surgical robotic solutions [7] Surgical Procedure Details - The telesurgery involved two One-Anastomosis Gastric Bypass (OAGB) surgeries, which are advanced bariatric procedures aimed at long-term weight loss and improved metabolic health [4][8] - The surgeries were performed remotely over a distance of 560 miles, showcasing the capabilities of the SSi Mantra 3 system with zero perceptible lag and flawless precision [3][8] Technological Advancements - The SSi Mantra surgical robotic system features a modular design with 3 to 5 robotic arms, an ergonomic command center, and advanced imaging capabilities, supporting various surgical specialties [11] - The system has been clinically validated in over 100 different types of surgical procedures in India, demonstrating its versatility and effectiveness [11] Vision and Impact - The company emphasizes its mission to democratize robotic surgery, bridging healthcare gaps and making advanced surgical care accessible to remote regions [5][6] - SS Innovations aims to redefine surgical care access, equity, and excellence through its innovative technologies and humanitarian vision [6]

Company Overview - SS Innovations International, Inc. is a developer of innovative surgical robotic technologies aimed at making robotic surgery affordable and accessible globally [3] - The company is headquartered in India and plans to expand its global presence with user-friendly and cost-effective surgical robotic solutions [3] Recent Developments - The first robotic cardiac surgery in the Americas was successfully performed using the SSi Mantra 3 surgical robotic system on June 8, 2025, by Dr. Juan Zuniga in Guayaquil, Ecuador [1] - The procedure involved a robotic Atrial Septal Defect closure, which repairs a hole between the upper two chambers of the heart [1] Technology Features - The SSi Mantra surgical robotic system is a modular, multi-arm system featuring advanced technology such as 3 to 5 robotic arms, a 3D 4K monitor, and a touch panel for patient information [4] - It utilizes over 40 different types of robotic endo-surgical instruments to support various specialties, including cardiac surgery [4] - The system has been clinically validated in India for over 100 different types of surgical procedures [4] Surgical Experience - Dr. Zuniga reported that the SSi Mantra system was easy to handle, resulting in effective outcomes and faster recovery for patients due to its minimally invasive nature [2] - The precision of the robotic system enhances the surgeon's confidence in performing sutures and tissue manipulation [2] Hospital Adoption - Interhospital in Guayaquil is the first hospital in South America to install the SSi Mantra system and has utilized it for various complex surgical procedures since its installation [2]

Core Insights - SS Innovations International, Inc. reported record quarterly revenue of $5.1 million for Q1 2025, a 40.8% increase from $3.6 million in Q1 2024, driven by higher sales of the SSi Mantra 3 surgical robotic system [4][6] - The company plans to submit a De Novo application to the FDA for the SSi Mantra 3 by the end of July 2025, aiming for approval in the U.S. and European markets [4][6] Financial Performance - Revenue increased by 40.8% to $5.1 million from $3.6 million in Q1 2024 [6] - Gross margin improved by 121 basis points to 21.23% from 20.02% in Q1 2024 [6] - Gross profit rose by 49.3% to $1.1 million from $0.7 million in Q1 2024 [6] - Net loss decreased to $5.7 million, or $(0.03) per diluted share, compared to a net loss of $9.8 million, or $(0.06) per diluted share, in Q1 2024 [6] Business Highlights - SSi Mantra installations totaled 15, a 66.7% increase from 9 installations in Q1 2024 [6] - Cumulative installed base of SSi Mantra reached 78, with cumulative surgeries totaling 3,568 [6][8] - Significant growth in instrument sales (302.7%) and warranty sales (1,202.3%) compared to Q1 2024 [8] Strategic Developments - The company uplisted to The Nasdaq Capital Market on April 25, 2025, marking a milestone for global expansion [3][4] - Plans to expand market presence beyond the seven countries where the SSi Mantra has been cleared, focusing on the EU and U.S. [4] Product Innovations - The SSi Mantra 3 surgical robotic system enabled the world's first robotic cardiac telesurgery [7] - The system received regulatory approvals in the Philippines and Ukraine, enhancing its market potential [7]

Core Insights - SS Innovations International, Inc. plans to submit a De Novo Classification Request to the FDA for the SSi Mantra 3 surgical robotic system in July 2025, aiming to enhance market access in the U.S. [1][2] Company Overview - SS Innovations is focused on developing innovative surgical robotic technologies to make robotic surgery affordable and accessible globally [6]. - The company has already marketed its SSi Mantra surgical robotic system in six countries and is pursuing further global expansion [5]. Product Performance - Since the launch of the SSi Mantra system in August 2022, 80 systems have been installed in 75 hospitals, with over 3,800 surgeries performed, including more than 200 robotic cardiac surgeries [3]. - The SSi Mantra 3 version, launched in June 2024, has seen 37 installations and over 750 multispecialty robotic surgical procedures, including 70 cardiac cases, with no device-related mortality or complications reported [3][4]. Clinical Validation - Real-world clinical data, validated by a leading contract research organization, supports the safety and efficacy of the SSi Mantra 3 for a variety of surgical procedures [4]. - The planned FDA submission will include applications for multispecialty indications such as urology, gynecology, general surgery, and thoracic and cardiac surgery [4]. Technological Features - The SSi Mantra Surgical Robotic System features a modular design with 3 to 5 robotic arms, an ergonomic surgeon command center, and advanced imaging capabilities, including a large 3D 4K monitor [7]. - It utilizes over 40 different types of robotic endo-surgical instruments to support various specialties, including cardiac surgery [7].